Starck Daniel J
Known title: EVP, President Patient DirectCIK: 0001345856
Associated companies
Transaction History
| ACH | ▼ Sell | Tax Withholding | 9,446 | $187K | 5/15/2024 | View on chart |
| ACH | ▲ Buy | Grant | 32,975 | $0 | 3/1/2024 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 2,139 | $40K | 5/15/2023 | View on chart |
| ACH | ▲ Buy | Grant | 52,624 | $0 | 3/1/2023 | View on chart |
| ACH | ▲ Buy | Grant | 21,598 | $0 | 5/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Accendra Health Receives NYSE Continued Listing Notice
Accendra Health received a notice from the NYSE regarding continued listing standards, with the company stating its intent to cure the deficiency. This regulatory development adds pressure to a stock that is already trading near its 52-week low. Additionally, Bank of America disclosed a 10.8% stake in the company as of September 30.
Accendra Health Receives NYSE Continued Listing Notice. Accendra Health received a notice from the NYSE regarding continued listing standards, with the company stating its intent to cure the deficiency. This regulatory development adds pressure to a stock that is already trading near its 52-week low. Additionally, Bank of America disclosed a 10.8% stake in the company as of September 30.